EASD 2017 In NHANES data, regularly drinking caffeinated coffee or tea was associated with lower mortality risk in women with diabetes, the protective effect varied with the source of caffeine.
EASD 2017 A posthoc analysis of data of the DUAL II and DUAL V studies showed that T2DM patients treated with insulin degludec/liraglutide had reduced CV risk factors than those treated with insulin.
EASD 2017 Two years after dieting, T2DM patients in a cognitive behavioral group therapy program showed similar weight regain and CV risk factors as those receiving standard care.
EASD 2017 Despite management by a multidisciplinary team, transgender persons with diabetes treated with hormones for gender confirmation had modifiable risk factors that aggravate diabetes.
EASD 2017 NHS provides the new, non-surgical, reversible weight loss Endobarrier device to help patients with poorly controlled T2DM and obesity kickstart a change in lifestyle.
EASD 2017 Subanalyses of EMPA-REG OUTCOME showed lower CV mortality risk in people with T2DM and established CV disease on empagliflozin treatment, irrespective of background blood sugar control.
EASD 2017 A new-generation, ultra-fast acting mealtime insulin aspart improved HbA1c and postprandial glucose control over 52 weeks, compared to conventional insulin aspart in T1DM.
EASD 2017 Post-hoc analysis of the SUSTAIN 1-5 trials shows that more adults with T2DM treated with semaglutide showed clinically meaningful reductions of HbA1c and body weight than those on comparator treatments.
EASD 2017 Scottish population-based data reveal that hospitalized people with T2DM and non-alcoholic fatty liver disease have an increased risk of CVD events and CV and all-cause mortality.
ESC 2017 The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.
Mendelian randomization provides evidence for possibly causal metabolic pathways of glucose homeostasis and T2DM, showing for instance that triglycerides and small HDL particles increase glucose.
First-in-human study showed that MobiusHD device that amplifies the baroreflex lowered BP and the need for antihypertensive treatment for up to 6 months, with acceptable safety.